Literature DB >> 27215221

Facioscapulohumeral Dystrophy.

Leo H Wang1, Rabi Tawil2.   

Abstract

Facioscapulohumeral muscular dystrophy (FSHD) is a clinically recognizable and relatively common muscular dystrophy. It is inherited mostly as an autosomal dominant disease or in a minority of cases, in a digenic pattern. The disease manifestation is variable and most likely dependent on genetic and epigenetic factors. We review the history, epidemiology, clinical presentation, and genetics of the disease, present the recently elucidated molecular pathogenesis, discuss the pathology and the possible consequence of the inflammation seen in the muscle biopsies, and consider future treatments.

Entities:  

Keywords:  DUX4; Facioscapulohumeral dystrophy; Genetics; Muscular dystrophy; SCHMD1

Mesh:

Year:  2016        PMID: 27215221     DOI: 10.1007/s11910-016-0667-0

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  60 in total

1.  Asymptomatic carriers and gender differences in facioscapulohumeral muscular dystrophy (FSHD).

Authors:  M M O Tonini; M R Passos-Bueno; A Cerqueira; S R Matioli; R Pavanello; M Zatz
Journal:  Neuromuscul Disord       Date:  2004-01       Impact factor: 4.296

2.  Studies in disorders of muscle. II Clinical manifestations and inheritance of facioscapulohumeral dystrophy in a large family.

Authors:  F H TYLER; F E STEPHENS
Journal:  Ann Intern Med       Date:  1950-04       Impact factor: 25.391

3.  DICER/AGO-dependent epigenetic silencing of D4Z4 repeats enhanced by exogenous siRNA suggests mechanisms and therapies for FSHD.

Authors:  Jong-Won Lim; Lauren Snider; Zizhen Yao; Rabi Tawil; Silvère M Van Der Maarel; Frank Rigo; C Frank Bennett; Galina N Filippova; Stephen J Tapscott
Journal:  Hum Mol Genet       Date:  2015-06-03       Impact factor: 6.150

4.  Inter-individual differences in CpG methylation at D4Z4 correlate with clinical variability in FSHD1 and FSHD2.

Authors:  Richard J L F Lemmers; Jelle J Goeman; Patrick J van der Vliet; Merlijn P van Nieuwenhuizen; Judit Balog; Marianne Vos-Versteeg; Pilar Camano; Maria Antonia Ramos Arroyo; Ivonne Jerico; Mark T Rogers; Daniel G Miller; Meena Upadhyaya; Jan J G M Verschuuren; Adolfo Lopez de Munain Arregui; Baziel G M van Engelen; George W Padberg; Sabrina Sacconi; Rabi Tawil; Stephen J Tapscott; Bert Bakker; Silvère M van der Maarel
Journal:  Hum Mol Genet       Date:  2014-09-25       Impact factor: 6.150

Review 5.  Polymyositis.

Authors:  C M Pearson
Journal:  Annu Rev Med       Date:  1966       Impact factor: 13.739

6.  DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy.

Authors:  Linda N Geng; Zizhen Yao; Lauren Snider; Abraham P Fong; Jennifer N Cech; Janet M Young; Silvere M van der Maarel; Walter L Ruzzo; Robert C Gentleman; Rabi Tawil; Stephen J Tapscott
Journal:  Dev Cell       Date:  2011-12-29       Impact factor: 12.270

7.  Aerobic training and postexercise protein in facioscapulohumeral muscular dystrophy: RCT study.

Authors:  Grete Andersen; Kira P Prahm; Julia R Dahlqvist; Gülsenay Citirak; John Vissing
Journal:  Neurology       Date:  2015-07-08       Impact factor: 9.910

8.  Individual epigenetic status of the pathogenic D4Z4 macrosatellite correlates with disease in facioscapulohumeral muscular dystrophy.

Authors:  Takako I Jones; Oliver D King; Charis L Himeda; Sachiko Homma; Jennifer C J Chen; Mary Lou Beermann; Chi Yan; Charles P Emerson; Jeffrey B Miller; Kathryn R Wagner; Peter L Jones
Journal:  Clin Epigenetics       Date:  2015-03-29       Impact factor: 6.551

9.  New Insights into Genotype-phenotype Correlations in Chinese Facioscapulohumeral Muscular Dystrophy: A Retrospective Analysis of 178 Patients.

Authors:  Feng Lin; Zhi-Qiang Wang; Min-Ting Lin; Shen-Xing Murong; Ning Wang
Journal:  Chin Med J (Engl)       Date:  2015-07-05       Impact factor: 2.628

10.  Large scale genotype-phenotype analyses indicate that novel prognostic tools are required for families with facioscapulohumeral muscular dystrophy.

Authors:  Giulia Ricci; Isabella Scionti; Francesco Sera; Monica Govi; Roberto D'Amico; Ilaria Frambolli; Fabiano Mele; Massimiliano Filosto; Liliana Vercelli; Lucia Ruggiero; Angela Berardinelli; Corrado Angelini; Giovanni Antonini; Elisabetta Bucci; Michelangelo Cao; Jessica Daolio; Antonio Di Muzio; Rita Di Leo; Giuliana Galluzzi; Elisabetta Iannaccone; Lorenzo Maggi; Valerio Maruotti; Maurizio Moggio; Tiziana Mongini; Lucia Morandi; Ana Nikolic; Ebe Pastorello; Enzo Ricci; Carmelo Rodolico; Lucio Santoro; Maura Servida; Gabriele Siciliano; Giuliano Tomelleri; Rossella Tupler
Journal:  Brain       Date:  2013-09-11       Impact factor: 13.501

View more
  40 in total

1.  Inhibition of DUX4 expression with antisense LNA gapmers as a therapy for facioscapulohumeral muscular dystrophy.

Authors:  Kenji Rowel Q Lim; Rika Maruyama; Yusuke Echigoya; Quynh Nguyen; Aiping Zhang; Hunain Khawaja; Sreetama Sen Chandra; Takako Jones; Peter Jones; Yi-Wen Chen; Toshifumi Yokota
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-29       Impact factor: 11.205

2.  Reduced serum myostatin concentrations associated with genetic muscle disease progression.

Authors:  Peter M Burch; Oksana Pogoryelova; Joe Palandra; Richard Goldstein; Donald Bennett; Lori Fitz; Michela Guglieri; Chiara Marini Bettolo; Volker Straub; Teresinha Evangelista; Hendrik Neubert; Hanns Lochmüller; Carl Morris
Journal:  J Neurol       Date:  2017-01-10       Impact factor: 4.849

Review 3.  Molecular Therapies for Muscular Dystrophies.

Authors:  Ava Y Lin; Leo H Wang
Journal:  Curr Treat Options Neurol       Date:  2018-06-21       Impact factor: 3.598

4.  Monosomy 18p is a risk factor for facioscapulohumeral dystrophy.

Authors:  Judit Balog; Remko Goossens; Richard J L F Lemmers; Kirsten R Straasheijm; Patrick J van der Vliet; Anita van den Heuvel; Chiara Cambieri; Nicolas Capet; Léonard Feasson; Veronique Manel; Julian Contet; Marjolein Kriek; Colleen M Donlin-Smith; Claudia A L Ruivenkamp; Patricia Heard; Stephen J Tapscott; Jannine D Cody; Rabi Tawil; Sabrina Sacconi; Silvère M van der Maarel
Journal:  J Med Genet       Date:  2018-03-21       Impact factor: 6.318

5.  Large family cohorts of lymphoblastoid cells provide a new cellular model for investigating facioscapulohumeral muscular dystrophy.

Authors:  Takako I Jones; Charis L Himeda; Daniel P Perez; Peter L Jones
Journal:  Neuromuscul Disord       Date:  2016-12-23       Impact factor: 4.296

Review 6.  Recent advancements in understanding the role of epigenetics in the auditory system.

Authors:  Rahul Mittal; Nicole Bencie; George Liu; Nicolas Eshraghi; Eric Nisenbaum; Susan H Blanton; Denise Yan; Jeenu Mittal; Christine T Dinh; Juan I Young; Feng Gong; Xue Zhong Liu
Journal:  Gene       Date:  2020-07-29       Impact factor: 3.688

Review 7.  Targeting mRNA for the treatment of facioscapulohumeral muscular dystrophy.

Authors:  Bo Bao; Rika Maruyama; Toshifumi Yokota
Journal:  Intractable Rare Dis Res       Date:  2016-08

Review 8.  Duchenne and Becker Muscular Dystrophies: A Review of Animal Models, Clinical End Points, and Biomarker Quantification.

Authors:  Kristin Wilson; Crystal Faelan; Janet C Patterson-Kane; Daniel G Rudmann; Steven A Moore; Diane Frank; Jay Charleston; Jon Tinsley; G David Young; Anthony J Milici
Journal:  Toxicol Pathol       Date:  2017-10-03       Impact factor: 1.902

Review 9.  Facioscapulohumeral dystrophy: activating an early embryonic transcriptional program in human skeletal muscle.

Authors:  Amy E Campbell; Andrea E Belleville; Rebecca Resnick; Sean C Shadle; Stephen J Tapscott
Journal:  Hum Mol Genet       Date:  2018-08-01       Impact factor: 6.150

10.  DUX4 Transcript Knockdown with Antisense 2'-O-Methoxyethyl Gapmers for the Treatment of Facioscapulohumeral Muscular Dystrophy.

Authors:  Kenji Rowel Q Lim; Adam Bittel; Rika Maruyama; Yusuke Echigoya; Quynh Nguyen; Yiqing Huang; Kasia Dzierlega; Aiping Zhang; Yi-Wen Chen; Toshifumi Yokota
Journal:  Mol Ther       Date:  2020-10-15       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.